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OBJECTIVES: Parkinson’s disease (PD) is a frequent and chronic
neurological disorder representing a growing burden for national
health care budgets. We assessed independent predictors for 1)
PD-speciﬁc drug costs; 2) direct non-drug costs’; and 3) indirect
costs METHODS: We analyzed data from an ongoing prospec-
tive cost study (n = 157) within the German PD Competence
Network using multivariate regression techniques. Potential pre-
dictors included sociodemographic factors, clinical data repre-
sented by the Uniﬁed Parkinson’s Disease Rating Scale (UPDRS),
disease severity (Hoehn&Yahr scale) and quality of life (QoL)
data. PD-speciﬁc drug costs and non-drug costs were log-trans-
formed prior to model development, resulting in multiplicative
models. Indirect costs were calculated using the human capital
approach. Model formulation proceeded in two steps: ﬁrst, pres-
ence of indirect costs was modeled by logistic regression, and
second, costs were predicted by linear regression in the subgroup
of patients with indirect costs. RESULTS: Predictors of PD-spe-
ciﬁc drugs included age, sex, clinical state (all p < 0.001) and
QoL (p = 0.02). Non-drug direct costs were predicted by disease
stage p = 0.05 and p < 0.001) and QoL (p = 0.03). Presence of
indirect costs depended on age (p < 0.001), UPDRS (p = 0.03),
QoL (p = 0.04), presence of depression (p = 0.02), and falls (p
= 0.006). The magnitude of indirect costs was predicted by
UPDRS (p = 0.003) and falls (p = 0.007). Variance explained by
the predictors (adjusted R-squared) ranged from 24% to 28%
for all models. CONCLUSIONS: Based on our analysis, clinical
and QoL variables are the most relevant predictors of PD cost.
However, we cannot infer from this study whether improved
QoL has an effect on PD costs, or is a consequence of more
expensive treatment.
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OBJECTIVES: Studies from Europe and the USA demonstrate
that entacapone + levodopa signiﬁcantly improves the function-
ality of Parkinson’s disease (PD) patients with wearing-off, and
is cost-effective compared to standard of care (SOC). This study
aimed to evaluate the cost-effectiveness of new levodopa/car-
bidopa/entacapone (Stalevo) vs. SOC in wearing-off patients in
the UK. METHODS: Cost-utility analysis was performed using
a Markov model based on Modiﬁed Hoehn and Yahr (H&Y)
stages. Transition probabilities were obtained from two multi-
national, double-blind RCTs. Mean costs and EQ-5D utilities of
local PD population were used with 3.5% discounting. NHS
drug costs were obtained from MIMS. Levodopa doses and
initial patient distribution by H&Y were derived from data of
wearing-off patients from a Finnish cost-of-illness study. Adap-
tations to local setting were based on expert opinions. Mean lev-
odopa/carbidopa/entacapone intake was 4.8 tablets/day. Both A)
societal and B) the NHS perspective was considered. Costs to
society included NHS costs, social costs and PD-related private
expenditures. RESULTS: A) New levodopa/carbidopa/enta-
capone treatment provided signiﬁcantly better quality of life
(QoL) for the patients (+0.817 QALYs). Simultaneously the costs
to society decreased by 8200GBP, mainly due to savings in social
costs and secondary care. The 10-year total direct costs to society
were 58,400GBP/patient on levodopa/carbidopa/entacapone. B)
Per patient the 10-year costs to NHS increased by 5500GBP,
resulting in total NHS costs of 26,300GBP. Thus, from the NHS
perspective, levodopa/carbidopa/entacapone was associated with
an incremental cost of 6700GBP/QALY gained. Both results
were robust to sensitivity analyses. CONCLUSIONS: New lev-
odopa/carbidopa/entacapone treatment provides better QoL for
wearing-off patients, simultaneously reducing the costs to UK
society, compared to SOC. Although the NHS costs slightly
increase, the incremental cost/QALY gained is relatively low.
Therefore, from a societal, as well as NHS perspective, use of
new levodopa/carbidopa/entacapone treatment in PD patients
with wearing-off is economically justiﬁed.
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OBJECTIVES: Retrospectively assess the total costs of Parkin-
son Disease (PD) in Italy from a societal perspective.
METHODS: We dispensed a questionnaire to PD patients
divided in three sections: Economic (14 items) Quality of life (36
items) Care Giver Burdens (8 items. We included 268 patients
with idiopathic PD, according to the CAPIT criteria. Those
patients are representative of the population of 7500 movement
disorder patients referring to our medical centre. The study pop-
ulation were divided in 3 groups accordingly to the classiﬁcation
of the Hoehn and Yahr staging scale. Costs of each group were
assessed. The distribution of patients is spread on all the Italian
territory. RESULTS: The mean annual direct cost of PD is
5639.12€. Drug therapy counts for 32.8% of total cost (1849€),
rehabilitation for 19.44% (1.096€), inpatient hospital care for
19.61% (1105.83€), “out of pocket” patient expenses (private
visits, paid rehabilitation, home care) count for 18.53%
(1044.93€), Specialist and Gp visit for 5.92% (333.84€). As the
severity of the disease grows the PD costs turns form National
Health System to patient “out of pocket” expenses. Costs are
signiﬁcantly higher when patient suffers from motor ﬂuctuations.
QoL reduces dramatically as the PD symptoms worsen. CON-
CLUSIONS: This study shows that PD represents a relevant
monetary burden for the society associated to a signiﬁcant
worsen of QoL. The total cost of this disease, based on an esti-
mation of 160.000 idiopathic PD patients in Italy, is about
€76,000,000 per year. Moreover, due to the demographic ten-
dency in our country we can assume an increase of this value in
the coming years.
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